Federal Circuit Upholds ITC Ruling on Ventria Bioscience Patent, Defining Domestic Industry Standards

In a recent precedential decision, the Federal Circuit has affirmed the U.S. International Trade Commission’s (ITC) earlier ruling involving Ventria Bioscience, a biotech developer based in the U.S. The ITC’s prior determination concluded that a Chinese vaccine developer had infringed upon Ventria’s cell culture patent. Critically, the Federal Circuit underscored the ITC’s stance on domestic industry requirements, asserting that there is no “threshold dollar value” associated with them. This ruling further indicates that “small market segments” within the biotech industry can satisfy such requirements, thereby supporting Ventria’s operations in the small but significant niche they occupy. Details of the decision can be accessed through Law360.